{
    "hands_on_practices": [
        {
            "introduction": "To truly grasp vancomycin resistance, we must go beyond qualitative descriptions and quantify its effect at the molecular level. This exercise connects the biochemical change in the peptidoglycan target to a fundamental thermodynamic principle: the Gibbs free energy of binding. By calculating the energetic penalty that the D-Ala-D-Lac modification imposes on vancomycin's binding affinity, you will gain a deeper, quantitative appreciation for why this resistance mechanism is so effective .",
            "id": "4641792",
            "problem": "An advanced pharmacodynamic analysis of glycopeptide binding in Vancomycin Resistant Enterococcus (VRE) is required. Consider the binding of vancomycin to the peptidoglycan precursor in Enterococcus faecium (E. faecium). In vancomycin-susceptible strains, the target terminus is D-alanyl-D-alanine, whereas in VanA-type resistant strains, the terminus is remodeled to D-alanyl-D-lactate, which is empirically observed to increase the dissociation constant by approximately $1000$-fold at physiological temperature $T=310$ $\\mathrm{K}$. Let the binding reaction be represented as $L + R \\rightleftharpoons LR$, where $L$ is vancomycin, $R$ is the target terminus, and $LR$ is the bound complex. Starting from the fundamental definitions of the association constant $K_{a}$ and dissociation constant $K_{d}$ for this equilibrium, and the thermodynamic definition of the standard Gibbs free energy change $\\Delta G^{\\circ}$ for an equilibrium process, derive the expression that links the standard binding free energy $\\Delta G^{\\circ}_{\\text{bind}}$ to $K_{d}$. Then, compute the change in standard binding free energy, $\\Delta \\Delta G^{\\circ}_{\\text{bind}}$, when $K_{d}$ increases $1000$-fold at $T=310$ $\\mathrm{K}$. Use the molar gas constant $R = 8.314$ $\\mathrm{J\\,mol^{-1}\\,K^{-1}}$. Express your numerical result in kilojoules per mole ($\\mathrm{kJ\\,mol^{-1}}$) and round your answer to four significant figures. Finally, interpret the pharmacological consequence for activity at a fixed extracellular vancomycin concentration by reasoning from receptor occupancy and thermodynamic favorability, without invoking any empirical minimum inhibitory concentration (MIC) values.",
            "solution": "The problem is assessed to be valid. It is scientifically grounded in the established biochemical basis of vancomycin resistance, well-posed with sufficient information for a unique solution, and expressed in objective, precise language. I will now proceed with the solution.\n\nThe problem requires a three-part solution: first, a derivation of the relationship between the standard binding free energy ($\\Delta G^{\\circ}_{\\text{bind}}$) and the dissociation constant ($K_d$); second, the calculation of the change in this free energy ($\\Delta \\Delta G^{\\circ}_{\\text{bind}}$) due to resistance; and third, an interpretation of the pharmacological consequences.\n\nPart 1: Derivation of the relationship between $\\Delta G^{\\circ}_{\\text{bind}}$ and $K_d$.\n\nThe binding reaction is given by the equilibrium:\n$$L + R \\rightleftharpoons LR$$\nwhere $L$ represents vancomycin (the ligand), $R$ represents the peptidoglycan precursor terminus (the receptor), and $LR$ is the bound complex.\n\nThe association constant, $K_a$, for this binding equilibrium is defined as the ratio of the concentration of the product to the concentrations of the reactants at equilibrium:\n$$K_a = \\frac{[LR]}{[L][R]}$$\nThe dissociation constant, $K_d$, is the reciprocal of the association constant and corresponds to the equilibrium constant for the reverse reaction, $LR \\rightleftharpoons L + R$:\n$$K_d = \\frac{1}{K_a} = \\frac{[L][R]}{[LR]}$$\nThe standard Gibbs free energy change for a reaction, $\\Delta G^{\\circ}$, is related to its equilibrium constant, $K_{eq}$, by the fundamental thermodynamic equation:\n$$\\Delta G^{\\circ} = -RT \\ln(K_{eq})$$\nwhere $R$ is the molar gas constant and $T$ is the absolute temperature.\n\nThe standard binding free energy, $\\Delta G^{\\circ}_{\\text{bind}}$, corresponds to the association process $L + R \\rightarrow LR$. The equilibrium constant for this process is $K_a$. Therefore, we can write:\n$$\\Delta G^{\\circ}_{\\text{bind}} = -RT \\ln(K_a)$$\nTo relate this to the dissociation constant, $K_d$, we substitute $K_a = 1/K_d$:\n$$\\Delta G^{\\circ}_{\\text{bind}} = -RT \\ln\\left(\\frac{1}{K_d}\\right)$$\nUsing the logarithmic identity $\\ln(1/x) = -\\ln(x)$, the expression becomes:\n$$\\Delta G^{\\circ}_{\\text{bind}} = -RT(-\\ln(K_d)) = RT \\ln(K_d)$$\nThis is the required expression linking the standard binding free energy to the dissociation constant. A more negative $\\Delta G^{\\circ}_{\\text{bind}}$ indicates stronger binding, which corresponds to a smaller $K_d$ value (note that for $K_d < 1$, $\\ln(K_d)$ is negative).\n\nPart 2: Calculation of the change in standard binding free energy, $\\Delta \\Delta G^{\\circ}_{\\text{bind}}$.\n\nLet the parameters for the vancomycin-susceptible (S) and vancomycin-resistant (R) strains be denoted by the subscripts $S$ and $R$, respectively.\nThe standard binding free energy for the susceptible strain is:\n$$\\Delta G^{\\circ}_{S} = RT \\ln(K_{d,S})$$\nThe standard binding free energy for the resistant strain is:\n$$\\Delta G^{\\circ}_{R} = RT \\ln(K_{d,R})$$\nThe change in standard binding free energy, $\\Delta \\Delta G^{\\circ}_{\\text{bind}}$, upon acquiring resistance is the difference between these two values:\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} = \\Delta G^{\\circ}_{R} - \\Delta G^{\\circ}_{S}$$\nSubstituting the expressions for the Gibbs free energies:\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} = RT \\ln(K_{d,R}) - RT \\ln(K_{d,S})$$\nFactoring out the $RT$ term and using the logarithmic identity $\\ln(a) - \\ln(b) = \\ln(a/b)$:\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} = RT \\ln\\left(\\frac{K_{d,R}}{K_{d,S}}\\right)$$\nThe problem states that the dissociation constant increases $1000$-fold in the resistant strain, which means the ratio $\\frac{K_{d,R}}{K_{d,S}} = 1000$.\nSubstituting the given values $R = 8.314$ $\\mathrm{J\\,mol^{-1}\\,K^{-1}}$ and $T = 310$ $\\mathrm{K}$:\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} = (8.314 \\mathrm{~J\\,mol^{-1}\\,K^{-1}}) \\times (310 \\mathrm{~K}) \\times \\ln(1000)$$\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} \\approx (2577.34 \\mathrm{~J\\,mol^{-1}}) \\times (6.907755)$$\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} \\approx 17804.55 \\mathrm{~J\\,mol^{-1}}$$\nTo express the answer in kilojoules per mole ($\\mathrm{kJ\\,mol^{-1}}$), we divide by $1000$:\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} \\approx 17.80455 \\mathrm{~kJ\\,mol^{-1}}$$\nRounding to four significant figures as requested gives:\n$$\\Delta \\Delta G^{\\circ}_{\\text{bind}} = 17.80 \\mathrm{~kJ\\,mol^{-1}}$$\n\nPart 3: Interpretation of the pharmacological consequence.\n\nThe positive value of $\\Delta \\Delta G^{\\circ}_{\\text{bind}} = +17.80 \\mathrm{~kJ\\,mol^{-1}}$ indicates that the binding of vancomycin to the D-alanyl-D-lactate target in the resistant strain is substantially less thermodynamically favorable than its binding to the D-alanyl-D-alanine target in the susceptible strain. This thermodynamic penalty directly translates to a reduced efficacy at the molecular level.\n\nTo formalize this, we consider the fractional receptor occupancy, $\\theta$, which is the fraction of target sites bound by the drug. For a simple $1:1$ binding equilibrium, $\\theta$ is given by the Hill-Langmuir equation:\n$$\\theta = \\frac{[L]}{[L] + K_d}$$\nThis equation demonstrates that for a fixed drug concentration $[L]$, the occupancy $\\theta$ is inversely related to the dissociation constant $K_d$.\n\nIn the resistant strain, $K_d$ is $1000$ times larger than in the susceptible strain ($K_{d,R} = 1000 \\times K_{d,S}$). At any given extracellular vancomycin concentration $[L]$, the target occupancy in the resistant strain ($\\theta_R$) will be drastically lower than in the susceptible strain ($\\theta_S$).\n\nFor example, at a vancomycin concentration equal to the $K_d$ of the susceptible strain, i.e., $[L] = K_{d,S}$:\n- Occupancy in the susceptible strain: $\\theta_S = \\frac{K_{d,S}}{K_{d,S} + K_{d,S}} = \\frac{1}{2} = 0.5$, or $50\\%$ occupancy.\n- Occupancy in the resistant strain: $\\theta_R = \\frac{K_{d,S}}{K_{d,S} + K_{d,R}} = \\frac{K_{d,S}}{K_{d,S} + 1000 K_{d,S}} = \\frac{1}{1001} \\approx 0.001$, or approximately $0.1\\%$ occupancy.\n\nThe pharmacological consequence is a profound failure of the drug to engage its target. Vancomycin's mechanism of action relies on binding to the peptidoglycan precursors to sterically hinder the transglycosylase and transpeptidase enzymes, thereby inhibiting cell wall synthesis. The $1000$-fold increase in $K_d$ means that a $1000$-fold higher concentration of vancomycin would be required to achieve the same level of target occupancy as in the susceptible strain. Such high concentrations are not clinically achievable or safe. Therefore, the remodeling of the target terminus from D-Ala-D-Ala to D-Ala-D-Lac confers resistance by making the drug-target binding event so thermodynamically unfavorable that effective target occupancy cannot be reached at therapeutic drug concentrations. This loss of affinity is the direct molecular cause of resistance.",
            "answer": "$$\\boxed{17.80}$$"
        },
        {
            "introduction": "Now that we understand the energetic consequence of the altered drug target, let's explore the elegant genetic machinery that *Enterococcus* uses to build it. The `vanA` operon is a coordinated system, and this practice challenges you to think like a molecular geneticist by predicting the outcome of disabling one part of the system. Understanding the specific role of each enzyme, such as VanX, is critical to appreciating how high-level resistance is achieved and maintained .",
            "id": "4628606",
            "problem": "An Enterococcus faecium strain carries the vanA-type operon responsible for vancomycin resistance and is grown in medium with abundant D-alanine and pyruvate. In vancomycin-resistant Enterococcus (VRE), resistance arises when peptidoglycan precursors terminate in D-alanine–D-lactate (D-Ala–D-Lac) rather than D-alanine–D-alanine (D-Ala–D-Ala), because vancomycin binds with high affinity to D-Ala–D-Ala termini but has markedly reduced affinity to D-Ala–D-Lac termini. The vanA operon encodes enzymes that redirect cell wall precursor synthesis: VanH converts pyruvate to D-lactate, VanA ligates D-alanine to D-lactate to form D-Ala–D-Lac, and VanX is a D,D-dipeptidase that hydrolyzes D-Ala–D-Ala to prevent its incorporation into peptidoglycan. The organism’s native D-Ala–D-Ala ligase (Ddl) remains present. Consider a genetic knockout that abolishes VanX expression, while other vanA operon components remain functional. Based on the Central Dogma of Molecular Biology (DNA to RNA to protein) and the well-established mechanism of vancomycin action (binding to the D-Ala–D-Ala terminus of peptidoglycan precursors via multiple hydrogen bonds), predict the net effect of the VanX knockout on the cellular pools of D-Ala–D-Ala versus D-Ala–D-Lac peptidoglycan precursors and the expected direction of change in the vancomycin Minimum Inhibitory Concentration (MIC). Choose the single best answer.\n\nA. D-Ala–D-Ala precursors increase and D-Ala–D-Lac precursors decrease; vancomycin MIC decreases into the susceptible range.\n\nB. D-Ala–D-Ala precursors decrease and D-Ala–D-Lac precursors increase; vancomycin MIC increases further.\n\nC. No significant change in either precursor pool due to pathway redundancy; vancomycin MIC remains unchanged.\n\nD. Both D-Ala–D-Ala and D-Ala–D-Lac precursors accumulate because degradation is impaired; vancomycin MIC increases due to cell wall stress.\n\nE. D-Ala–D-Lac precursors selectively increase because VanA and VanH remain active; vancomycin MIC decreases.",
            "solution": "### Step 1: Extract Givens\n\n-   **Organism**: An *Enterococcus faecium* strain.\n-   **Genetic element**: Carries the *vanA*-type operon.\n-   **Growth medium**: Contains abundant D-alanine and pyruvate.\n-   **Resistance mechanism**: In vancomycin-resistant *Enterococcus* (VRE), resistance is due to peptidoglycan precursors terminating in D-alanine–D-lactate (D-Ala–D-Lac) instead of D-alanine–D-alanine (D-Ala–D-Ala).\n-   **Vancomycin action**: Binds with high affinity to D-Ala–D-Ala termini and low affinity to D-Ala–D-Lac termini.\n-   ***vanA* operon enzyme functions**:\n    -   VanH: Converts pyruvate to D-lactate.\n    -   VanA: A ligase that forms the dipeptide D-Ala–D-Lac.\n    -   VanX: A D,D-dipeptidase that hydrolyzes D-Ala–D-Ala.\n-   **Native enzyme**: The host's original D-Ala–D-Ala ligase, Ddl, is present and functional.\n-   **Experimental condition**: A genetic knockout abolishes VanX expression. Other *vanA* operon components (VanH, VanA) remain functional.\n-   **Question**: Predict the net effect of the VanX knockout on the cellular pools of D-Ala–D-Ala versus D-Ala–D-Lac precursors and the direction of change in the vancomycin Minimum Inhibitory Concentration (MIC).\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement describes the well-established and scientifically correct mechanism of *vanA*-mediated vancomycin resistance in *Enterococcus*. The functions attributed to the enzymes VanH, VanA, VanX, and the native Ddl are factually accurate. The premises regarding vancomycin's mode of action—preferential binding to D-Ala–D-Ala termini—are a cornerstone of medical microbiology. The posed question is a logical \"what-if\" scenario based on a standard experimental technique (genetic knockout) and requests a prediction based on the interplay of defined biochemical pathways. The problem is self-contained, scientifically grounded, objective, and well-posed. No flaws are identified.\n\n### Step 3: Verdict and Action\n\nThe problem is **valid**. A solution will be derived.\n\n### Derivation of Solution\n\nThe problem requires an analysis of competing biochemical pathways for peptidoglycan precursor synthesis in a *vanA*-positive *Enterococcus faecium* strain following a targeted gene knockout.\n\n**1. Baseline State (Wild-Type *vanA* Function)**\n\nIn a typical *vanA*-positive VRE strain, two parallel pathways for dipeptide synthesis exist:\n-   **Native Pathway**: The native Ddl enzyme uses two molecules of D-alanine to synthesize the dipeptide D-Ala–D-Ala. This is the natural precursor for cell wall synthesis in susceptible bacteria.\n-   **Resistance Pathway**: The *vanA* operon provides a new pathway. VanH converts pyruvate into D-lactate. VanA then ligates one molecule of D-alanine with one molecule of D-lactate to form the depsipeptide D-Ala–D-Lac.\n\nFor high-level resistance to be achieved, the cell must ensure that only D-Ala–D-Lac precursors are incorporated into the growing peptidoglycan. This is where VanX plays a critical role. VanX is a D,D-dipeptidase that specifically hydrolyzes D-Ala–D-Ala into two D-alanine molecules, effectively removing the susceptible precursor from the cytoplasmic pool. The net result is a cell wall built almost exclusively with D-Ala–D-Lac-terminated precursors, to which vancomycin cannot bind effectively. This results in a high vancomycin MIC.\n\n**2. State After VanX Knockout**\n\nThe experimental condition is a knockout of the gene encoding VanX, while all other enzymes remain functional. Let us analyze the consequences:\n\n-   The native Ddl enzyme continues its function, producing D-Ala–D-Ala from the abundant D-alanine substrate.\n-   The VanH and VanA enzymes also continue their functions, producing D-Ala–D-Lac.\n-   The crucial change is the absence of the VanX enzyme. The D-Ala–D-Ala dipeptides synthesized by Ddl are no longer hydrolyzed.\n\n**3. Effect on Precursor Pools**\n\n-   **D-Ala–D-Ala Pool**: Without the degradative activity of VanX, the pool of D-Ala–D-Ala dipeptides will **increase** substantially from its near-zero level in the parent VRE strain. These dipeptides are now available for incorporation into peptidoglycan precursors.\n-   **D-Ala–D-Lac Pool**: The production pathway for D-Ala–D-Lac (VanH and VanA) remains intact. However, the cellular system now contains a competing substrate for the enzymes that add the dipeptide to the UDP-MurNAc-tripeptide. The accumulation of D-Ala–D-Ala shifts the balance of available precursors. The net synthesis of D-Ala–D-Lac might decrease due to substrate competition for D-alanine (used by both Ddl and VanA) or other regulatory feedbacks, but more importantly, its *relative proportion* in the total pool of precursors will dramatically decrease. Therefore, describing the effect as a decrease in the D-Ala–D-Lac pool is reasonable, especially in a relative sense.\n\n**4. Effect on Vancomycin MIC**\n\nVancomycin's bactericidal action relies on its ability to form a stable complex with the D-Ala–D-Ala terminus of peptidoglycan precursors, physically blocking the transglycosylation and transpeptidation steps of cell wall assembly.\n\n-   In the VanX knockout mutant, a significant population of peptidoglycan precursors will now terminate in D-Ala–D-Ala.\n-   These precursors serve as high-affinity targets for vancomycin.\n-   Binding of vancomycin to these targets will successfully inhibit cell wall synthesis.\n-   Consequently, the organism's resistance to vancomycin will be compromised, and it will become more susceptible.\n-   An increase in susceptibility is measured as a **decrease** in the Minimum Inhibitory Concentration (MIC). The cell is inhibited by a lower concentration of the drug.\n\n**Summary of Prediction:** The VanX knockout will lead to an increase in the cellular pool of D-Ala–D-Ala precursors. This restores the target for vancomycin, causing the vancomycin MIC to decrease, rendering the strain more susceptible.\n\n### Option-by-Option Analysis\n\n**A. D-Ala–D-Ala precursors increase and D-Ala–D-Lac precursors decrease; vancomycin MIC decreases into the susceptible range.**\n-   **D-Ala–D-Ala precursors increase**: This is correct. The removal of the degradative enzyme VanX will cause the product of Ddl, D-Ala–D-Ala, to accumulate.\n-   **D-Ala–D-Lac precursors decrease**: This is plausible. The accumulation of a competing precursor and potential substrate competition for D-alanine would likely lead to a relative or absolute decrease in the D-Ala–D-Lac pool.\n-   **vancomycin MIC decreases into the susceptible range**: This is correct. The re-emergence of the susceptible D-Ala–D-Ala target restores vancomycin's efficacy, thus lowering the MIC.\n-   **Verdict: Correct.** This option accurately describes the primary biochemical and pharmacological consequences.\n\n**B. D-Ala–D-Ala precursors decrease and D-Ala–D-Lac precursors increase; vancomycin MIC increases further.**\n-   **D-Ala–D-Ala precursors decrease**: Incorrect. The knockout of an enzyme that degrades a molecule will cause that molecule's concentration to increase, not decrease.\n-   **D-Ala–D-Lac precursors increase**: Incorrect. There is no mechanism described that would cause the knockout of VanX to upregulate the VanH/VanA pathway.\n-   **vancomycin MIC increases further**: Incorrect. The MIC will decrease as the cell becomes more susceptible.\n-   **Verdict: Incorrect.**\n\n**C. No significant change in either precursor pool due to pathway redundancy; vancomycin MIC remains unchanged.**\n-   **No significant change**: Incorrect. The function of VanX is specific and non-redundant. Its removal has a major impact on the D-Ala–D-Ala pool. It is a critical component for maintaining the resistance phenotype, not a redundant part.\n-   **vancomycin MIC remains unchanged**: Incorrect. The MIC is directly dependent on the composition of the precursor pool.\n-   **Verdict: Incorrect.**\n\n**D. Both D-Ala–D-Ala and D-Ala–D-Lac precursors accumulate because degradation is impaired; vancomycin MIC increases due to cell wall stress.**\n-   **Both precursors accumulate**: Incorrect. VanX specifically degrades D-Ala–D-Ala. Its absence does not impair the degradation or turnover of D-Ala–D-Lac.\n-   **vancomycin MIC increases**: Incorrect. The reintroduction of the susceptible target lowers the MIC. While cell wall stress can sometimes induce resistance pathways, the primary effect in this context is the restoration of susceptibility.\n-   **Verdict: Incorrect.**\n\n**E. D-Ala–D-Lac precursors selectively increase because VanA and VanH remain active; vancomycin MIC decreases.**\n-   **D-Ala–D-Lac precursors selectively increase**: Incorrect. While VanA and VanH remain active, there is no reason for their product to *selectively increase*. The most significant change is the accumulation of D-Ala–D-Ala.\n-   **vancomycin MIC decreases**: This part of the statement is correct, but the reasoning provided for it in the first part of the option is flawed.\n-   **Verdict: Incorrect.** The justification for the change in precursor pools is wrong.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "The emergence of vancomycin-resistant *Enterococcus* (VRE) poses a significant clinical challenge, forcing us to find alternative treatment strategies. This final practice moves from understanding the mechanism to overcoming it, focusing on the concept of antibiotic synergy. You will use experimental data to calculate the Fractional Inhibitory Concentration Index (FICI), a key metric that helps clinicians decide if a combination of drugs can work together to defeat a resistant pathogen .",
            "id": "4641751",
            "problem": "A patient with infective endocarditis due to an Enterococcus faecalis isolate harboring the VanA-type vancomycin resistance determinant is being evaluated for beta-lactam synergy as an alternative to vancomycin. In vitro susceptibility testing yields the following minimum inhibitory concentrations (MICs): the MIC for ampicillin alone is 2, and for ceftriaxone alone is 1024. A checkerboard assay is performed, and the first well along the inhibition interface (no visible growth) contains ampicillin 0.25 combined with ceftriaxone 64.\n\nUsing the standard definition of the fractional inhibitory concentration index (FICI) derived from MICs measured alone and in combination in a checkerboard assay, compute the FICI for the ampicillin–ceftriaxone combination for this isolate, and use widely accepted interpretive thresholds to decide whether the interaction is synergistic or merely additive/indifferent. Report only the numeric FICI as your final answer. Provide your answer as an exact value (no rounding) and do not include units.",
            "solution": "The task is to compute the fractional inhibitory concentration index (FICI) from checkerboard assay data and then interpret it using accepted thresholds for synergy versus additivity/indifference.\n\nFoundational definitions and facts:\n- The minimum inhibitory concentration (MIC) of a drug is the lowest concentration that inhibits visible bacterial growth under standardized conditions.\n- In a checkerboard assay, combinations of two drugs are tested across a two-dimensional dilution series to identify inhibitory pairs.\n- The fractional inhibitory concentration (FIC) of a drug in a combination is defined as the ratio of its concentration in the inhibitory combination to its MIC when used alone.\n- The fractional inhibitory concentration index (FICI) is defined as the sum of the two FICs for the pair of drugs.\n- Widely used interpretive thresholds categorize interactions as synergistic when the FICI is less than or equal to $0.5$, additive/indifferent when greater than $0.5$ and up to $1$, and antagonistic when greater than $1$ (with some schemes using higher cutoffs for strong antagonism).\n\nGiven data:\n- Ampicillin MIC alone = 2.\n- Ceftriaxone MIC alone = 1024.\n- Inhibitory combination well: ampicillin = 0.25, ceftriaxone = 64.\n\nCompute individual FICs:\n- For ampicillin, the FIC is the combination concentration divided by the MIC alone:\n$$\n\\text{FIC}_{\\text{ampicillin}} \\;=\\; \\frac{0.25}{2} \\;=\\; \\frac{1}{8} \\;=\\; 0.125.\n$$\n- For ceftriaxone, the FIC is:\n$$\n\\text{FIC}_{\\text{ceftriaxone}} \\;=\\; \\frac{64}{1024} \\;=\\; \\frac{1}{16} \\;=\\; 0.0625.\n$$\n\nSum to obtain the FICI:\n$$\n\\text{FICI} \\;=\\; \\text{FIC}_{\\text{ampicillin}} \\;+\\; \\text{FIC}_{\\text{ceftriaxone}} \\;=\\; \\frac{1}{8} \\;+\\; \\frac{1}{16} \\;=\\; \\frac{2}{16} \\;+\\; \\frac{1}{16} \\;=\\; \\frac{3}{16}.\n$$\n\nInterpretation:\n- Since $\\frac{3}{16} \\;=\\; 0.1875 \\;\\leq\\; 0.5$, this interaction is categorized as synergistic by widely accepted thresholds used in infectious diseases pharmacodynamics and clinical microbiology.\n\nThe problem requests that only the numeric FICI be reported as the final answer, in exact form and without units. The exact value is $\\frac{3}{16}$.",
            "answer": "$$\\boxed{\\frac{3}{16}}$$"
        }
    ]
}